In vitro experiments have indicated that CTS inhibits the viability of human NSCLC cells (A549 and H460), partly via down-regulating cyclin A/D and CDK2/4, thus blocking the cell cycle in G0/G1 phase141. Here, CDK2 is linked to non-small cell lung carcinoma.